Huisheng Biotechnology: Intends to permanently supplement working capital with the surplus funds raised of 35.958 million yuan.

According to the announcement of Sheng Biology, the company held the fourth session of the tenth meeting of the Board of Directors on June 25, 2026, and reviewed and passed the resolution on the completion of the fundraising project and the permanent supplement of the remaining raised funds for working capital. The company agreed to issue convertible corporate bonds to unspecified investors to raise funds for the investment projects "expansion of the production line of 1000 tons of Taile antibiotics and 600 tons of Taiwan antibiotics per year" and "1000 tons of Taile antibiotics per year", and to use the remaining raised funds to permanently supplement working capital.